Page last updated: 2024-11-05

tridemorph

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tridemorph is a triazole fungicide that is used to control powdery mildew diseases in a variety of crops. It is synthesized via a multi-step process involving the reaction of 1-chloro-2,4-dinitrobenzene with 1,2,4-triazole, followed by several subsequent reactions. Tridemorph has a broad spectrum of activity against powdery mildew fungi, including those that infect wheat, barley, grapes, apples, and other fruits. It is known to inhibit the biosynthesis of ergosterol, an important component of fungal cell membranes, leading to fungal cell death. Tridemorph has been a widely used fungicide due to its effectiveness and low cost. However, concerns about its potential environmental and health risks, including its persistence in the environment and its potential to disrupt endocrine systems, have led to a decline in its use in some countries. Despite these concerns, tridemorph continues to be studied for its potential as a fungicide and for its ability to control other pests, such as insects and nematodes. Research on tridemorph focuses on understanding its mode of action, its potential effects on the environment and human health, and its potential for development into new and improved pesticides.'

tridemorph: RN given refers to cpd with unspecified isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tridemorph : A mixture of 4-alkyl-2,6-dimethylmorpholines, where 'alkyl' is a mixture of C11 to C14 homologues of which 60-70% is tridecyl. A systemic fungicide, it is no longer approved for use within the European Union. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2,6-dimethyl-4-tridecylmorpholine : A member of the class of morpholines that is 2,6-dimethylmorpholine in which the hydrogen attached to the nitrogen is replaced by a tridecyl group. The configuration at positions 2 and 6 is unknown or unspecified. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID32518
CHEMBL ID2286765
CHEBI ID83365
SCHEMBL ID28670
MeSH IDM0064911

Synonyms (66)

Synonym
81412-43-3
AC-19786
4-tridecyl-2,6-dimethylmorpholine
morpholine, 2,6-dimethyl-n-tridecyl-
n-tridecyl-2,6-dimethylmorpholine
nsc-232676
basf 220f
f 220 (fungicide)
morpholine,6-dimethyl-4-tridecyl-
bas 2203f
calixin
calixine
nsc232676
brn 0608429
bas 2205-f
n-tridecyl-2,6-dimethylmorpholin [german]
epa pesticide chemical code 121401
einecs 246-347-3
nsc 232676
e-236
tridemorph [iso]
caswell no. 386
24602-86-6
tridemorph
2,6-dimethyl-4-tridecylmorpholine
tridemorf [czech]
dimethyl-2,6 tridecyl-4 morpholine [french]
tridemorphe [iso-french]
tridemorph [bsi:iso]
tridemorphe
morpholine, 2,6-dimethyl-4-tridecyl-
2,6-dimethyl-4-tridecyl-morpholine
kalixin
kalinin
FT-0651743
A840125
NCGC00248097-01
tridemorpn
tox21_300591
dtxcid1021376
dtxsid3041376 ,
NCGC00254333-01
cas-24602-86-6
A817389
tridemorf
unii-0yz4z668ey
0yz4z668ey ,
dimethyl-2,6 tridecyl-4 morpholine
784443kx6h ,
unii-784443kx6h
n-tridecyl-2,6-dimethylmorpholin
FT-0630893
AKOS015914987
SCHEMBL28670
CHEMBL2286765
elbamorph
tridemorph, pestanal(r), analytical standard
bdbm50487253
2,6-dimethyl-n-tridecyl-morpholine
J-015587
Q209280
CHEBI:83365
(2xi,6xi)-2,6-dimethyl-4-tridecylmorpholine
tridemorph (mix of isomers)
ZAA60286
AS-76727

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A significant dose-response effect was observed between the number of risk alleles, rs11134527A and rs2566 T, and the risk of cervical cancer (P for trend=0."( Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women.
Chen, X; Han, S; Hu, L; Hu, Z; Li, Y; Pan, L; Qiang, F; Shen, H; Wu, Y; Zhou, X, 2010
)
0.36
" Lamellar biopsies were obtained prior to dosing and at intervals during the treatment period for analysis (at 12, 18, 24, 30 and 36 h and at 48 h following euthanasia)."( The timeline of lamellar basement membrane changes during equine laminitis development.
Pollitt, CC; Visser, MB, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antifungal agrochemicalAny substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
morpholinesAny compound containing morpholine as part of its structure.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.53570.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.09620.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743191
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.48270.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency50.41690.143427.612159.8106AID1159516; AID1159519
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DeltaZea maysIC50 (µMol)25.00000.03001.27673.0000AID1092250
Cycloeucalenol cycloisomeraseZea maysIC50 (µMol)0.40000.20000.33330.4000AID1092249
Sterol-8,7-isomeraseZea maysIC50 (µMol)0.40000.08000.42000.8000AID1092248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1092249Inhibition of Zea mays (maize) cycloeucalenol-obtusifolial isomerase1989European journal of biochemistry, Nov-20, Volume: 185, Issue:3
Microsomal delta 8,14-sterol delta 14-reductase in higher plants. Characterization and inhibition by analogues of a presumptive carbocationic intermediate of the reduction reaction.
AID1092248Inhibition of Zea mays (maize) delta8,delta7-sterol isomerase1989European journal of biochemistry, Nov-20, Volume: 185, Issue:3
Microsomal delta 8,14-sterol delta 14-reductase in higher plants. Characterization and inhibition by analogues of a presumptive carbocationic intermediate of the reduction reaction.
AID1092250Inhibition of Zea mays (maize) microsomal delta 8,14-steroid 14-reductase using delta 8,14-cholestadienol as substrate after 90 min by GC analysis1989European journal of biochemistry, Nov-20, Volume: 185, Issue:3
Microsomal delta 8,14-sterol delta 14-reductase in higher plants. Characterization and inhibition by analogues of a presumptive carbocationic intermediate of the reduction reaction.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (954)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (1.78)18.7374
1990's222 (23.27)18.2507
2000's381 (39.94)29.6817
2010's294 (30.82)24.3611
2020's40 (4.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.48 (24.57)
Research Supply Index6.91 (2.92)
Research Growth Index5.74 (4.65)
Search Engine Demand Index54.30 (26.88)
Search Engine Supply Index2.39 (0.95)

This Compound (33.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.70%)5.53%
Reviews50 (5.02%)6.00%
Case Studies136 (13.64%)4.05%
Observational0 (0.00%)0.25%
Other804 (80.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]